Open AccessUpdate on emerging biomarkers in lung cancer
Author(s) -
Eric H. Bernicker,
Timothy Craig Allen,
Phillip T. Cagle
Publication year - 2019
Publication title -
journal of thoracic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 60
eISSN - 2077-6624
pISSN - 2072-1439
DOI - 10.21037/jtd.2019.01.46
Subject(s) - medicine , lung cancer , biomarker , disease , biomarker discovery , cancer , targeted therapy , bioinformatics , molecular biomarkers , precision medicine , intensive care medicine , oncology , pathology , proteomics , gene , biology , biochemistry
There has been considerable progress made in identifying oncogenic driver mutations in advanced lung cancer. The recognition that lung cancer is actually an umbrella classification that is comprised of multiple molecular subgroups has had a profound impact on how medical oncologists make treatment decisions. These mutations are clinically important as available targeted therapies can achieve significant responses and prolonged disease control. This review will summarize the current guidelines for biomarker testing and available therapeutic agents.